Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
Hiren PatelKamlesh Khunti F MedSciHelena W RodbardHarpreet S BajajRoss BrayZbigniew KindrackiAngel RodríguezPublished in: Diabetes, obesity & metabolism (2023)
Superior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.